Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvanted human papillomavirus vaccine recombinant nonavalent - Merck

Next Previous
X
Search
Drug Profile

Adjuvanted human papillomavirus vaccine recombinant nonavalent - Merck

Alternative Names: 9-valent HPV L1 vaccine adjuvanted with AAHS and ISCOMATRIX™ - Merck; 9-valent HPV L1 VLP-AAHS/IMX vaccine - Merck; Adjuvanted HPV L1 VLP 9-valent vaccine - Merck; Adjuvanted human papillomavirus L1 virus-like-particle nonavalent vaccine - Merck; Broad-spectrum human papillomavirus vaccine - Merck; V-505

Latest Information Update: 10 Feb 2014

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 24 Jun 2011 Merck & Co completes a phase IIa trial in Cervical cancer and Human papillomavirus infections in Australia and New Zealand (NCT00520598)
  • 22 Mar 2010 Phase-II development is ongoing in Australia and New Zealand
  • 25 Oct 2007 Phase-II clinical trials in Cervical cancer in Australia (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top